Amgen Inc.'s well-designed GAUSS-3 study shows a role of its PCSK9 inhibitor Repatha in patients who truly can't tolerate statins, but how this translates into real-world utilization in the highly cost-conscious cardiology space remains to be seen.
GAUSS-3 tested the cholesterol-lowering ability of Repatha (evolocumab) in about 500 patients who could not tolerate a low dose of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
